ACQUIPHARMA HOLDINGS

Bugworks Research said it will continue to invest in its proprietary drug discovery platforms GYROX (for AMR) and DARE (for Immuno-oncology...

The latest capital raise will allow the company to complete its phase-1 studies for its GYROX series intravenous drug candidate, as well as...